AIM
NBSE

Advantage Investment Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Advantage Investment Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-5
Closed -$6K – 936
2016
Q1 		$6K Hold
5
– – ﹤0.01% 663
2015
Q4 		$12K Hold
5
– – 0.01% 542
2015
Q3 		$6K Hold
5
– – ﹤0.01% 637
2015
Q2 		$5K Buy
+5
New +$5.39K ﹤0.01% 706

Other funds holding NBSE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
SIP
Stoneridge Investment Partners Radnor, Pennsylvania $138M AUM 7.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Advantage Investment Management's NBSE Position: Q2 2016 in Review

Advantage Investment Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2016, closing a stake of 5 shares — an estimated $6K sold.

Advantage Investment Management first reported a position in NBSE in Q2 2015 and held it in 4 quarters. The position peaked at $12K in Q4 2015. 51 funds tracked by Wall St. Rank hold NBSE as of Q2 2016.

  • Advantage Investment Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
  • Advantage Investment Management sold 5 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2016, an estimated $6K.
  • Advantage Investment Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2015 and held it in 4 quarters.
  • Advantage Investment Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $12K in Q4 2015.
  • 51 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2016.

Based on Advantage Investment Management's 13F filing for Q2 2016, filed 27 Mar 2017.